ARCT:NSD-Arcturus Therapeutics Holdings Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 45.54

Change

-5.05 (-9.98)%

Market Cap

USD 1.33B

Volume

1.48M

Average Target Price

USD 75.75 (+66.34%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.65 (-0.31%)

USD54.19B 20.26 15.08
MRNA Moderna, Inc

+1.08 (+0.82%)

USD52.46B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

+2.65 (+0.59%)

USD47.86B 14.64 11.87
ALXN Alexion Pharmaceuticals, Inc

+0.27 (+0.18%)

USD32.58B 54.48 33.22
BGNE BeiGene, Ltd

-15.33 (-5.03%)

USD29.17B N/A N/A
SGEN Seagen Inc

-2.48 (-1.68%)

USD26.80B 43.90 37.70
RPRX Royalty Pharma plc

-1.23 (-2.82%)

USD26.45B 22.60 14.17
BNTX BioNTech SE

-2.10 (-2.16%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.63 (-5.01%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARCT

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Daily S&P Biotec.. 0.00 % 1.04 %

-8.79 (-9.51%)

USD0.34B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.98% 52% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.98% 52% F 50% F
Trailing 12 Months  
Capital Gain 149.40% 86% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 149.40% 86% B 88% B+
Trailing 5 Years  
Capital Gain 38.71% 61% D- 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.71% 61% D- 42% F
Average Annual (5 Year Horizon)  
Capital Gain 114.40% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 114.40% 92% A- 96% A
Risk Return Profile  
Volatility (Standard Deviation) 201.49% 11% F 6% F
Risk Adjusted Return 56.78% 82% B- 76% C
Market Capitalization 1.33B 76% C 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.58 69% D+ 48% F
Price / Cash Flow Ratio -31.02 83% B 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -34.17% 74% C 29% F
Return on Invested Capital -31.62% 74% C 25% F
Return on Assets -16.00% 74% C 23% F
Debt to Equity Ratio 3.49% 72% C- 84% B
Technical Ratios  
Short Ratio 1.91 55% F 53% F
Short Percent 13.70% 15% F 13% F
Beta 2.99 4% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector